Männel DN, Moore RN, Mergenhagen SE. Macrophages as a source of tumoricidal activity (tumor-necrotizing factor). Infect Immun. 1980;30:523–30.
Ruff MR, Gifford GE. Rabbit tumor necrosis factor: mechanism of action. Infect Immun. 1981;31:380–5.
Broide DH, Lotz M, Cuomo AJ, Coburn DA, Federman EC, Wasserman SI. Cytokines in symptomatic asthma airways. J Allergy Clin Immunol. 1992;89:958–67.
Chung KF, Barnes PJ. Cytokines in asthma. Thorax. 1999;54:825–57.
Giguère S, Viel L, Lee E, MacKay RJ, Hernandez J, Franchini M. Cytokine induction in pulmonary airways of horses with heaves and effect of therapy with inhaled fluticasone propionate. Vet Immunol Immunopathol. 2002;85:147–58.
Franchini M, Gill U, von Fellenberg R, Bracher VD. Interleukin-8 concentration and neutrophil chemotactic activity in bronchoalveolar lavage fluid of horses with chronic obstructive pulmonary disease following exposure to hay. Am J Vet Res. 2000;61:1369–74.
Morris DD, Moore JN, Crowe N. Serum tumor necrosis factor activity in horses with colic attributable to gastrointestinal tract disease. Am J Vet Res. 1991;52:1565–9.
De la Rebière de Pouyade G, Serteyn D. The role of activated neutrophils in the early stage of equine laminitis. Vet J. 2011;189:27–33.
Pirie RS. Recurrent airway obstruction: a review. Equine Vet J. 2014;46:276–88.
Laan TT, Bull S, Pirie R, Fink-Gremmels J. The role of alveolar macrophages in the pathogenesis of recurrent airway obstruction in horses. J Vet Intern Med. 2006;20:167–74.
Woodward EM. Troedsson, M H T. Inflammatory mechanisms of endometritis. Equine Vet J. 2015;47:384–9.
Werners AH, Bull S, Fink-Gremmels J. Endotoxaemia: a review with implications for the horse. Equine Vet J. 2005;37:371–83.
Beutler B, Cerami A. The biology of cachectin/TNF--a primary mediator of the host response. Annu Rev Immunol. 1989;7:625–55.
MacKay RJ. Inflammation in horses. Vet Clin North Am Equine Pract. 2000;16:15–27.
Lavoie-Lamoureux A, Beauchamp G, Quessy S, Martin JG, Lavoie JP. Systemic inflammation and priming of peripheral blood leukocytes persist during clinical remission in horses with heaves. Vet Immunol Immunopathol. 2012;146:35–45.
Morris DD, Moore JN. Tumor necrosis factor activity in serum from neonatal foals with presumed septicemia. J Am Vet Med Assoc. 1991;199:1584–9.
DeForge LE, Remick DG. Kinetics of TNF, IL-6, and IL-8 gene expression in LPS-stimulated human whole blood. Biochem Biophys Res Commun. 1991;174:18–24.
Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett. 1991;285:199–212.
Sheron N, Lau J, Daniels H, Goka J, Eddleston A, Alexander GJ, et al. Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection. J Hepatol. 1991;12:241–5.
Bradham CA, Plümpe J, Manns MP, Brenner DA, Trautwein C. Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am J Physiol. 1998;275:387–92.
van der Poll T, van Deventer SJ, ten Cate H, Levi M, ten Cate JW. Tumor necrosis factor is involved in the appearance of interleukin-1 receptor antagonist in endotoxemia. J Infect Dis. 1994;169:665–7.
Christoffersen M, Woodward E, Bojesen AM, Jacobsen S, Petersen MR, Troedsson MH, Lehn-Jensen H. Inflammatory responses to induced infectious endometritis in mares resistant or susceptible to persistent endometritis. BMC Vet Res. 2012;29:8:41.
Bullone M, Lavoie JP. Asthma “of horses and men”--how can equine heaves help us better understand human asthma immunopathology and its functional consequeces? Mol Immunol. 2015;66:97–105.
Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood. 1991;77:1627–52.
Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today. 1991;12:404–10.
Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002;13:323–40.
Granowitz EV, Santos AA, Poutsiaka DD, Cannon JG, Wilmore DW, Wolff SM, et al. Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet. 1991;338:1423–4.
Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol. 1998;16:27–55.
McColl SR, Paquin R, Menard C, Beaulieu AD. Human neutrophils produce high levels of the interleukin I receptor antagonist in response to granulocyte/macrophage colony-stimulating factor and tumor necrosis factor-a. J Exp Med. 1992;176:593–8.
Martel-Pelletier J, McCollum R, Pelletier JP. The synthesis of IL-I receptor antagonist (IL-I ra) by synovial fibroblasts is markedly increased by the cytokines TNF-a and IL-l. Biochim Biophys Acta. 1993;1175:302–5.
Damsgaard CT, Lauritzen L, Calder PC, Kjaer TM, Frøkiaer H. Whole-blood culture is a valid low-cost method to measure monocytic cytokines - a comparison of cytokine production in cultures of human whole-blood, mononuclear cells and monocytes. J Immunol Methods. 2009;340:95–101.
Richard EA, Depecker M, Defontis M, Leleu C, Fortier G, Pitel P, et al. Cytokine concentrations in bronchoalveolar lavage fluid from horses with neutrophilic inflammatory airway disease. J Vet Intern Med. 2014;28:1838–44.
McFarlane D, Holbrook TC. Cytokine dysregulation in aged horses and horses with pituitary pars intermedia dysfunction. J Vet Intern Med. 2008;22:436–42.
MacKay RJ, King RR, Dankert JR, Reis KJ, Skelley LA. Cytotoxic tumor necrosis factor activity produced by equine alveolar macrophages: preliminary characterization. Vet Immunol Immunopathol. 1991;29:15–30.
Morris DD, Moore JN, Fischer K, Tarleton RL. Endotoxin-induced tumor necrosis factor activity production by equine peritoneal macrophages. Circ Shock. 1990;30:229–36.
Karagianni AE, Kapetanovic R, McGorum BC, Hume DA, Pirie SR. The equine alveolar macrophage: functional and phenotypic comparisons with peritoneal macrophages. Vet Immunol Immunopathol. 2013;155:219–28.
Strieter RM, Remick DG, Ham JM, Colletti LM, Lynch 3rd JP, Kunkel SL. Tumor necrosis factor-alpha gene expression in human whole blood. J Leukoc Biol. 1990;47:366–70.
Yaqoob P, Newsholme EA, Calder PC. Comparison of cytokine production in cultures of whole human blood and purified mononuclear cells. Cytokine. 1999;11:600–5.
De Groote D, Zangerle PF, Gevaert Y, Fassotte MF, Beguin Y, Noizat-Pirenne F, et al. Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I Comparison with isolated PBMC stimulation. Cytokine. 1992;4:239–48.
Morris DD, Crowe N, Moore JN. Correlation of clinical and laboratory data with serum tumor necrosis factor activity in horses with experimentally induced endotoxemia. Am J Vet Res. 1990;51:1935–40.
Cudmore LA, Muurlink T, Whittem T, Bailey SR. Effects of oral clenbuterol on the clinical and inflammatory response to endotoxaemia in the horse. Res Vet Sci. 2013;94:682–6.
Alcott CJ, Sponseller BA, Wong DM, Davis JL, Soliman AM, Wang C, et al. Clinical and immunomodulating effects of ketamine in horses with experimental endotoxemia. J Vet Intern Med. 2011;25:934–43.
Langereis JD, Oudijk ED, Schweizer RC, Lammers JJ, Koenderman L, Ulfman LH. Steroids induce a disequilibrium of secreted interleukin-1 receptor antagonist and interleukin-1β synthesis by human neutrophils. Eur Respir J. 2011;37:406–15.
Marie C, Pitton C, Fitting C, Cavaillon JM. IL-10 and IL-4 synergize with TNF-alpha to induce IL-1ra production by human neutrophils. Cytokine. 1996;8:147–51.
Marsh CB, Wewers MD. Cytokine-induced interleukin-1 receptor antagonist release in mononuclear phagocytes. Am J Respir Cell Mol Biol. 1994;10:521–5.
Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest. 1997;99:2930–40.
Gabay C, Gigley J, Sipe J, Arend WP, Fantuzzi G. Production of IL-1 receptor antagonist by hepatocytes is regulated as an acute-phase protein in vivo. Eur J Immunol. 2001;31:490–9.